Puja P Khanna, MD, MPH
Clinical Professor of Internal Medicine
Service Chief, Internal Medicine
Medical School
[email protected]

Available to mentor
Puja P Khanna, MD, MPH
Clinical Professor
  • Center Memberships
  • Recent Publications
    • Manage Your Profile
    Center Memberships
    • Center Member
      Institute for Healthcare Policy and Innovation
    Recent Publications See All Publications
    • Journal Article
      The Rheumatologist as the Agent of Change: Utility of Guidelines in the Management of Gout
      Khanna PP. Journal of Rheumatology, 2025 Jan 1; 52 (1): 4 - 5. DOI:10.3899/jrheum.2024-0957
      PMID: 39406406
    • Proceeding / Abstract / Poster
      Impact of Anti-drug Antibodies on the Efficacy of SEL-212 in Patients with Chronic Gout Refractory to Conventional Therapy
      Khanna P. 2024 Nov 17;
    • Proceeding / Abstract / Poster
      Improvements in Patient-Reported Outcomes After Treatment with SEL-212 in Adults with Refractory Gout: Results from Two Randomized Phase 3 Trials
      Khanna P, Strand V. 2024 Nov 17;
    • Proceeding / Abstract / Poster
      Inpatient Discontinuation of Allopurinol - A Qualitative Improvement (QI) Initiative
      Khanna P, Al-Dulaijan B, Tancer S. 2024 Nov 17;
    • Journal Article
      Efficacy and Safety of SEL-212 in Patients with Refractory Gout and CKD: A Post Hoc Analysis from the Two Phase 3 DISSOLVE Studies
      Khanna P, Johnson RJ, Azeem R, Falk A, Desai B, Santin-Janin H, Baraf H, Kivitz AJ. Journal of the American Society of Nephrology, 2024 Oct 30; 35 (10S): 10.1681/asn.202457c52mh7 DOI:10.1681/asn.202457c52mh7
    • Journal Article
      POS0260 ONCE-MONTHLY SEL-212 DEMONSTRATES EFFICACY AND SAFETY FOR UP TO 6-MONTHS IN GOUT REFRACTORY TO CONVENTIONAL THERAPY: COMBINED DATA FROM THE DISSOLVE I & II PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIALS
      Baraf HSB, Khanna P, Patel A, Singhal A, Sobierska J, Santin-Janin H, Azeem R, Dehaan W, Traber P, Kivitz A. Annals of the Rheumatic Diseases, 2024 Jun 12; 83: 408 - 409. DOI:10.1136/annrheumdis-2024-eular.2832
    • Journal Article
      P084 Gout symptom improvements and patient outcomes with SEL-212 in gout refractory to conventional therapy: DISSOLVE I & II phase 3, double-blind, placebo-controlled clinical trials
      Baraf HSB, Khanna P, Patel A, Sobierska J, Christie J, DeHaan W, Azeem R, Traber PG, Kivitz A. Rheumatology, 2024 Apr 25; 63 (Supplement_1): keae163.125 DOI:10.1093/rheumatology/keae163.125
    • Journal Article
      The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR<sup>TM</sup>) versus pegloticase for refractory gout
      Baraf HSB, Khanna PP, Kivitz AJ, Strand V, Choi HK, Terkeltaub R, Dalbeth N, DeHaan W, Azeem R, Traber PG, Keenan RT. Rheumatology (United Kingdom), 2024 Apr 1; 63 (4): 1058 - 1067. DOI:10.1093/rheumatology/kead333
      PMID: 37449908